Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Lobeline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.97 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.97 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.97 |
| ▸ | SLC18A2 known ✓ | Q05940 | 1/20 | 0.97 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.97 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lobeline SCHEMBL467021 | 1.00 | CYP2D6 (0.97) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL8305826 | 0.99 | CYP2D6 (1.00) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL14029403 | 0.99 | CYP2D6 (1.00) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL3308906 | 0.99 | CYP2D6 (1.00) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL13900378 | 0.99 | CYP2D6 (1.00) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL2905547 | 0.99 | CYP2D6 (1.00) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL290804 | 0.99 | CYP2D6 (1.00) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL290803 | 0.99 | CYP2D6 (1.00) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL4264391 | 0.97 | CYP2D6 (0.97) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL8994428 | 0.97 | CYP2D6 (0.97) | CYP2D6CYP1A2TSHRNFKB1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113981020-B | Method for synthesizing lobelin hydrochloride intermediate by enzyme catalytic chiral reduction | 江苏恒盛药业有限公司 | 2024-09-10 | — | — | CN | claimed |
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| CN-112920107-B | Synthetic method of lobeline hydrochloride | 上海万巷制药有限公司 | 2022-09-13 | — | — | CN | claimed |
| CN-110646621-B | Application of CHRNA4 in preparation of drug for treating non-alcoholic steatohepatitis | 中国药科大学 | 2022-07-01 | — | — | CN | claimed |
| CN-113981020-A | Method for synthesizing lobeline hydrochloride intermediate by enzymatic chiral reduction | 江苏恒盛药业有限公司 | 2022-01-28 | — | — | CN | claimed |
| CN-113582912-A | Preparation method of optically pure lobeline hydrochloride and enantiomer thereof | 广东药科大学 | 2021-11-02 | — | — | CN | claimed |
| CN-112920107-A | Synthetic method of lobeline hydrochloride | 上海万巷制药有限公司 | 2021-06-08 | — | — | CN | claimed |
| CN-110721086-A | Preparation method of lobeline hydrochloride injection | 北京市永康药业有限公司 | 2020-01-24 | — | — | CN | claimed |
| CN-110646621-A | Application of CHRNA4 in preparation of drug for treating non-alcoholic steatohepatitis | 中国药科大学 | 2020-01-03 | — | — | CN | claimed |
| EP-2254579-B1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | ESTEVE LABOR DR (ES) | 2018-01-10 | — | — | EP | claimed |
| US-20110052723-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-03 | — | — | US | claimed |
| WO-2010015029-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2010-02-11 | — | — | WO | claimed |
| EP-2090311-A1 | Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-08-19 | — | — | EP | claimed |
| US-20090181976-A1 | Use of Compounds Binding to the Sigma Receptor for the Treatment of Metabolic Syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-07-16 | — | — | US | claimed |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | claimed |
| EP-1829534-A1 | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | claimed |
| CN-1988896-A | Use of compounds active on the sigma receptor for the treatment of mechanical allodynia | ESTEVE LABOR DR (ES) | 2007-06-27 | — | — | CN | claimed |
| EP-1787679-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| CN-1618956-A | Virus strain for preventing poultry influenza and its animal infection model | WUHAN INST OF VIROLOGY CAS (CN) | 2005-05-25 | — | — | CN | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | OPRM1, OPRL1, OPRK1 | HTR2A 56/4885HRH1 195/4885CHRNA7 11/4885 |
| US-20090181976-A1 | Use of Compounds Binding to the Sigma Receptor for the Treatment of Metabolic Syndrome | SIGMAR1, GPR119, TMEM97 | HTR2A 28/4885HRH1 566/4885CHRNA7 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.